Univariate and multivariate logistic regression analysis of preoperative predictors at 1-, 3- and 5-year postoperative success.

<p>Univariate and multivariate logistic regression analysis of preoperative predictors at 1-, 3- and 5-year postoperative success.</p

Criteria for determining the 1-, 3-, and 5-yr efficacy of individual domains (symptoms, QoL, and function) and proportion of patients for each efficacy grade.

<p>Criteria for determining the 1-, 3-, and 5-yr efficacy of individual domains (symptoms, QoL, and function) and proportion of patients for each efficacy grade.</p

Preoperative and perioperative profiles of all patients.

<p>Preoperative and perioperative profiles of all patients.</p

Usefulness of the frequency-volume chart over the International Prostate Symptom Score in patients with benign prostatic hyperplasia in view of global polyuria

<div><p>Purpose</p><p>We aimed to determine the usefulness of the frequency-volume chart over the International Prostate Symptom Score in patients with benign prostatic hyperplasia. Furthermore, we investigated the clinical characteristics suggesting that patients could benefit from frequency-volume chart assessment in addition to International Prostate Symptom Score assessment.</p><p>Methods</p><p>A total of 193 patients with benign prostatic hyperplasia were analyzed. The relationship between the information obtained from the frequency-volume chart and the International Prostate Symptom Score was assessed. Because the urine output per kilogram per hour was not associated with any question in the International Prostate Symptom Score questionnaire, patients were divided into 2 groups according to the presence of global polyuria, defined as urine output >40 mL·kg^-1·h^-1. Multivariable analysis was performed to determine the predictors of global polyuria, and the results were externally validated using 397 patients with benign prostatic hyperplasia.</p><p>Results</p><p>Although the other information obtained from the frequency-volume chart correlated with the International Prostate Symptom Score, the urine output was not associated with the International Prostate Symptom Score. Based on these results, patients were dichotomized into the global polyuria group (n = 19, 9.8%) and the non-global polyuria group. Although the patient characteristics did not differ between the 2 groups, the number of voids was higher in patients with global polyuria. Multivariable analysis showed that diabetes mellitus (odds ratio: 3.497, <i>p</i> = 0.039) and increased number of voids (odds ratio: 1.320, <i>p</i> < 0.001) were significant predictors of global polyuria. On external validation, the area under curve for the model was 0.723.</p><p>Conclusions</p><p>Global polyuria cannot be suspected using the International Prostate Symptom Score, although it worsens the lower urinary tract symptoms of patients with benign prostatic hyperplasia. Assessment with the frequency-volume chart needs to be considered in diabetic patients with increased number of voids.</p></div

Patient characteristics according to the presence of global polyuria.

<p>Patient characteristics according to the presence of global polyuria.</p

ROC curves of the prediction model for the presence of global polyuria.

<p>ROC curves of the prediction model for the presence of global polyuria.</p

Patient characteristics and biopsy outcomes according to glycemic control of DM.

<p>DM, diabetes mellitus, DM−, no DM; DM+GC, DM with good glycemic control, HbA1c <6.5%; DM+PC, DM with poor glycemic control, HbA1c ≥6.5%; PSA, prostate-specific antigen; PSAD, prostate-specific antigen density; DRE, digital rectal examination; Pca, prostate cancer; GS, Gleason Score.</p><p>Patient characteristics and biopsy outcomes according to glycemic control of DM.</p

Relationship between each question in the I-PSS questionnaire and components of frequency volume chart.

<p>(1) Question 1 (24-hour UO; <i>p</i> = 0.950, Nocturnal UO; <i>p</i> = 0.379, MVV; <i>p</i> = 0.205, Daytime voids; <i>p</i> = 0.475, Nocturnal voids; <i>p</i> = 0.080). (2) Question 2 (24-hour UO; <i>p</i> = 0.537, Nocturnal UO; <i>p</i> = 0.518, MVV; <i>p</i> = 0.001, Daytime voids; <i>p</i><0.001, Nocturnal voids; <i>p</i> = 0.001). (3) Question 3 (24-hour UO; <i>p</i> = 0.210, Nocturnal UO; <i>p</i> = 0.644, MVV; <i>p</i> = 0.109, Daytime voids; <i>p</i> = 0.250, Nocturnal voids; <i>p</i> = 0.467). (4) Question 4 (24-hour UO; <i>p</i> = 0.227, Nocturnal UO; <i>p</i> = 0.282, MVV; <i>p</i> = 0.032, Daytime voids; <i>p</i> = 0.010, Nocturnal voids; <i>p</i> = 0.055). (5) Question 5(24-hour UO; <i>p</i> = 0.556, Nocturnal UO; <i>p</i> = 0.488, MVV; <i>p</i> = 0.141, Daytime voids; <i>p</i> = 0.423, Nocturnal voids; <i>p</i> = 0.323). (6) Question 6 (24-hour UO; <i>p</i> = 0.265, Nocturnal UO; <i>p</i> = 0.377, MVV; <i>p</i> = 0.471, Daytime voids; <i>p</i> = 0.417, Nocturnal voids; <i>p</i> = 0.418). (7) Question 7 (24-hour UO; <i>p</i> = 0.629, Nocturnal UO; <i>p</i> = 0.041, MVV; <i>p</i> = 0.132, Daytime voids; <i>p</i> = 0.133, Nocturnal voids; <i>p</i><0.001). (8) Quality of life (24-hour UO; <i>p</i> = 0.374, Nocturnal UO; <i>p</i> = 0.390, MVV; <i>p</i> = 0.006, Daytime voids; <i>p</i> = 0.021, Nocturnal voids; <i>p</i> = 0.003).</p

Variables predicting global polyuria: Univariate and multivariable analysis.

<p>Variables predicting global polyuria: Univariate and multivariable analysis.</p

The relationship between each question in the I-PSS questionnaire with 24-hr Urine output / body weight.

<p>The relationship between each question in the I-PSS questionnaire with 24-hr Urine output / body weight.</p